Using messenger RNA (mRNA) differential display, we identified a single complementary DNA (cDNA) fragment (HG23T1) that was over-expressed in a hepatocellular carcinoma (HCC) specimen. We cloned the full-length HG23T1 gene by the rapid amplification of cDNA end (RACE) polymerase chain reaction (PCR) method. It perfectly matched the gene encoding human ribosomal protein L36a (RPL36A also referred to as RPL44). RPL36A mRNA was preferentially over-expressed in 34 of 40 HCC cases (85%, P < .001) and in all of 8 HCC cell lines. Ectopically over-expressed L36a ribosomal protein localized in the nucleoli of cells, and this localization seemed to be controlled by the N-terminal or the internal tetrapeptide consensus with its adjacent N-terminal domain. Over-expression of L36a led to enhanced colony formation and cell proliferation, which may have resulted from rapid cell cycling, and an antisense cDNA effectively reversed these alterations. In conclusion, RPL36A plays a role in tumor cell proliferation and may be a potential target for anticancer therapy of HCC. (HEPATOLOGY 2004;39:129 -138.) H epatocellular carcinoma (HCC) is a major malignancy with an increasing incidence worldwide. 1 The major risk factors for development of HCC are cirrhosis, chronic viral hepatitis B and C, exposure to aflatoxin, alcohol, and/or iron overload. HCCs are highly resistant to chemotherapeutic agents and radiotherapy. 2 Despite a variety of treatment options, including surgical resection, chemoembolization, percutaneous injection of ethanol, radiofrequency thermal ablation, and liver transplantation, the prognosis for HCC is poor. [3][4][5] Thus, the need to discover effective therapeutic molecules to suppress the growth of HCC is urgent. One approach is to find target genes and their molecular products and understanding how genetic and molecular changes can lead to cancer development through multistep carcinogenesis.Altered gene expression caused either by mutations or by changes in the regulatory characteristics of HCC compared with corresponding nontumor tissues have been reported. 6 -8 Such alterations can occur in various cell cycle-related oncogenes, such as c-myc, K-ras, and H-ras, and/or in tumor suppressor genes, such as retinoblastoma and p53. 9 -12 In addition, glutamine synthetase, alfa-fetoprotein (AFP), the insulin receptor substrate-1-like gene, cyclin D1, MAGE-1, HIP/PAP, and CD24 have been reported to be over-expressed during hepatocarcinogenesis. [13][14][15][16][17][18][19] However, these genetic changes do not precisely reflect the biologic nature or clinical characteristics of all HCCs. Previously, we identified and reported genes that were differentially expressed in HCC cells using the differential-display polymerase chain reaction (PCR) method. 20 Among them, we focused preferentially on an up-regulated gene in human HCC in comparison with the nontumor surrounding tissues. This gene later proved to encode the ribosomal protein L36a (RPL36A) protein, which is localized in the nucleolus.The biogenesis of eukary...